|
|
|
| NPM1 Mutations in K562 Cells Inhibits Cell Proliferation and Invasion in Vitro |
| SHAO Hui-yuan, MIAO Zong-yu, QIN Feng-xian, CHEN Xian-chun, TAN Shi, ZHONG Liang, ZHANG Ling |
| Key Laboratory of Laboratory Medical Diagnostics, Ministry of Education, Faculty of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, China |
|
|
|
Abstract Nucleophosmin (NPM1) mutations, described recently, play an important role in acute myeloid leukemia. To investigate the role of NPM1 mutations in K562 leukemic cell proliferation and invasion in vitro, the pEGFPC1-NPM1-mA plasmid vector with NPM1 mutation A (NPM1-mA) was transfected into K562 cells, and the K562-mA cells with stably expressed NPM1-mA protein were established. Cell growth curve was used to determine the proliferation potential in vitro. FCM was used to detect the cell cycle. Cell adhesion assay and Transwell were used to detect the adhesion, migration and invasion capability. The results showed that the proliferation potential of K562-mA cells was decreased. Compared with control groups, the percentage of cells in the G1 phase was increased remarkably and that in the S phase was decreased significantly. In addition, the migration ability of K562-mA cells was enhanced, but the adhesion and invasion capability of cells were attenuated.NPM1 mutations may inhibit K562 cells proliferation and invasion in vitro, which provide a better foundation for studying the molecule mechanisms of NPM1 mutations in leukemiagenesis.
|
|
Received: 20 July 2010
Published: 19 November 2010
|
|
|
|
|
| [1] Falini B, Bolli N, Liso A, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia, 2009, 23(10):1731- 1743.
[2] Meani N, Alcalay M. Role of nucleophosmin in acute myeloid leukemia. Expert Rev Anticancer Ther, 2009, 9(9):1283-1294.
[3] Zhang Y, Zhang M, Yang L, et al. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. Leukemia Research, 2007, 31(1): 109-111.
[4] Piccaluga P P, Sabattini E, Bacci F, et al. Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. Leukemia, 2009, 23 (7): 1370- 1371.
[5] Cheng K, Grisendi S, Clohessy J G, et al. The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. Oncogene, 2007, 26(53):7391-7400.
[6] den Besten W, Kuo M L, Williams R T, et al. Myeloid Leukemia-Associated Nucleophosmin Mutants Perturb p53-Dependent and Independent Activities of the Arf Tumor Suppressor Protein. Cell Cycle, 2005, 4(11): 1593-1598.
[7] Bonetti P, Davoli T, Sironi C, et al. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7γ. J Cell Biol, 2008, 182(1): 19-26.
[8] Falini B, Nicoletti I, Martelli M F, et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood, 2007, 109(3):874-885.
[9] Schneider F, Hoster E, Unterhalt M, et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood, 2009, 113(21):5250-5253.
[10] Falini B, Mecucci C, Tiacci E,et al. Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype. N Engl J Med, 2005, 352(3): 254- 266.
[11] Zhang W, Navenot J M, Frilot N M, et al. Association of nucleophosmin negatively regulates CXCR4-mediated G protein activation and chemotaxis. Mol Pharmacol, 2007, 72(5):1310-1321. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
